Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Oncologist
; 23(9): 1004-e102, 2018 09.
Article
in En
| MEDLINE
| ID: mdl-29769385
Full text:
1
Database:
MEDLINE
Main subject:
Esophageal Neoplasms
/
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Irinotecan
/
Panitumumab
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2018
Type:
Article